Authors : Kashish Rajput; Shubhanshu Soni; Aaditya Singh Sendhav

Volume/Issue : Volume 11 - 2026, Issue 10 - October

Google Scholar : https://tinyurl.com/y8tr73wr

DOI : https://doi.org/10.38124/ijisrt/26Oct882

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Nanotechnology-based hepatoprotective drug delivery systems constitute a significant paradigm shift in contemporary pharmacology, providing innovative strategies to circumvent the limitations inherent in conventional therapeutic approaches for hepatic disorders. Liver diseases—including cirrhosis, hepatitis, and non-alcoholic fatty liver disease—remain substantial global health burdens owing to their multifactorial etiology and the paucity of effective treatment modalities. The clinical utility of traditional hepatoprotective agents, whether synthetic or phytochemical, is frequently restricted by poor aqueous solubility, inadequate bioavailability, rapid metabolic clearance, and the absence of site-specific targeting capabilities. Nanotechnology offers a promising platform to overcome these constraints through the design and implementation of nanoscale drug delivery systems that enhance the solubility, stability, and controlled release profiles of therapeutic compounds. A diverse array of nanocarriers—including liposomes, solid lipid nanoparticles, polymeric nanoparticles, dendrimers, and nanoemulsions— has demonstrated marked improvements in pharmacokinetic and pharmacodynamic parameters. These systems enable targeted delivery to hepatic tissues, thereby increasing drug accumulation at the intended site of action while reducing systemic distribution and associated off-target toxicity. Moreover, nanotechnology significantly augments the delivery and therapeutic efficacy of bioactive phytoconstituents—such as curcumin, resveratrol, and silymarin—by enhancing their bioavailability and physicochemical stability. The capacity of nanocarriers to facilitate combination therapy through the co-encapsulation and co-delivery of multiple therapeutic agents provides a comprehensive strategy for managing multifactorial liver diseases. Not with standing these advantages, several challenges remain, including concerns regarding nanomaterial toxicity, physicochemical instability, elevated manufacturing costs, and regulatory hurdles. Consequently, rigorous preclinical investigations and well-designed clinical studies are imperative to ensure the safety, efficacy, and successful clinical translation of nano-technology based hepatoprotective drug delivery systems.

Keywords : Nanotechnology, Hepatoprotective Drug Delivery, Liver Disease, Nanocarriers, Liposome, Targeted Drug Delivery.

References :

1. Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. Journal of Hepatology, 70(1), 151–171. https://doi.org/10.1016/j.jhep.2018.09.014
2. Marcellin, P., & Kutala, B. K. (2020). Liver diseases: A major, neglected global public health problem requiring urgent actions. Clinical Liver Disease, 15(3), 105–109. https://doi.org/10.1002/cld.896
3. Moon, A. M., Singal, A. G., & Tapper, E. B. (2020). Contemporary epidemiology of chronic liver disease and cirrhosis. Clinical Gastroenterology and Hepatology, 18(12), 2650–2666. https://doi.org/10.1016/j.cgh.2019.07.060
4. Younossi, Z. M., & Henry, L. (2021). The impact of obesity and type 2 diabetes on chronic liver disease. Journal of Hepatology, 74(4), 970–980. https://doi.org/10.1016/j.jhep.2021.01.010
5. Abenavoli, L., Capasso, R., Milic, N., & Capasso, F. (2019). Milk thistle in liver diseases: Past, present, future. Phytotherapy Research, 24(10), 1423–1432. https://doi.org/10.1002/ptr.3207
6. Bansal, S., & Goel, M. (2019). Silymarin-loaded solid lipid nanoparticles: A promising approach for hepatoprotection. Journal of Drug Delivery Science and Technology, 52, 781–788. https://doi.org/10.1016/j.jddst.2019.05.045
7. Bilia, A. R., Piazzini, V., Guccione, C., Risaliti, L., & Bergonzi, M. C. (2019). Nanomedicine for the delivery of natural compounds with hepatoprotective activity. Expert Opinion on Drug Delivery, 16(5), 489–503. https://doi.org/10.1080/17425247.2019.1604672
8. Loguercio, C., & Festi, D. (2020). Silybin and the liver: From basic research to clinical practice. World Journal of Gastroenterology, 26(27), 3859–3872. https://doi.org/10.3748/wjg.v26.i27.3859
9. Paumgartner, G., & Beuers, U. (2020). Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology, 36(3), 525–531. https://doi.org/10.1053/jhep.2002.36088
10. Sadowska-Woda, I., & Bieszczad-Bedrejczuk, E. (2020). N-acetylcysteine in the treatment of drug-induced liver injury. Current Drug Metabolism, 21(5), 357–366. https://doi.org/10.2174/1389200221666200523152543
11. Polyzos, S. A., & Kountouras, J. (2020). Corticosteroids in autoimmune hepatitis: Current concepts and future directions. Annals of Gastroenterology, 33(2), 123–134. https://doi.org/10.20524/aog.2020.0453
12. Chung, R. T., & Baumert, T. F. (2021). Advances in antiviral therapy for hepatitis B and C. Nature Reviews Gastroenterology & Hepatology, 18(5), 305–317. https://doi.org/10.1038/s41575-021-00423-z
13. Kaur, I. P., & Bhandari, R. (2020). Silymarin-loaded nanocarriers: A promising approach for hepatoprotection. Drug Delivery and Translational Research, 10(3), 641–658. https://doi.org/10.1007/s13346-020-00733-6
14. Gupta, S., & Kesarla, R. (2021). Nanotechnology in hepatoprotective drug delivery: Current trends and future perspectives. Journal of Pharmaceutical Innovation, 16(3), 657–672. https://doi.org/10.1007/s12247-020-09512-5
15. Akhter, S., Ahmad, I., & Ahmad, M. Z. (Eds.). (2022). Nanocarriers for drug delivery: Concepts and applications. Springer.
16. Farokhzad, O. C., & Langer, R. (2019). Impact of nanotechnology on drug delivery. ACS Nano, 13(3), 2678–2689. https://doi.org/10.1021/acsnano.9b01770
17. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101–124. https://doi.org/10.1038/s41573-020-0090-8
18. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. P., Acosta-Torres, L. S., & Shin, H. S. (2020). Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 16(1), 71. https://doi.org/10.1186/s12951-018-0392-8
19. Rizvi, S. A., & Saleh, A. M. (2020). Applications of nanoparticle systems in drug delivery technology. Saudi Pharmaceutical Journal, 28(12), 1693–1705. https://doi.org/10.1016/j.jsps.2020.10.012
20. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2019). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108
21. Torchilin, V. P. (2020). Multifunctional nanocarriers for drug delivery. Advanced Drug Delivery Reviews, 158, 2–15. https://doi.org/10.1016/j.addr.2020.06.008
22. Zhang, L., & Wang, H. (2020). Clinical translation of nanomedicines for liver diseases: Challenges and opportunities. Advanced Therapeutics, 3(5), 1900198. https://doi.org/10.1002/adtp.201900198
23. Petros, R. A., & DeSimone, J. M. (2020). Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), 615–627. https://doi.org/10.1038/nrd2591
24. Singh, R., & Lillard, J. W., Jr. (2020). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215–223. https://doi.org/10.1016/j.yexmp.2008.12.004
25. Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T., & Tan, W. (2020). Nanotechnology in therapeutics: A focus on nanoparticles as drug delivery systems. Nanomedicine, 7(8), 1253–1271. https://doi.org/10.2217/nnm.12.87
26. Raj, S., & Jose, S. (2020). Liposomes for liver-targeted drug delivery: A review. Journal of Liposome Research, 30(4), 325–339. https://doi.org/10.1080/08982104.2019.1674321
27. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., … & Nejati-Koshki, K. (2019). Liposome: Classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102. https://doi.org/10.1186/1556-276X-8-102
28. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2020). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6, 286. https://doi.org/10.3389/fphar.2015.00286
29. Duan, Y., Dhar, A., Patel, C., Khimani, M., Neogi, S., & Sharma, P. (2020). A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC Advances, 10(45), 26777–26791. https://doi.org/10.1039/D0RA03491F
30. Ghasemiyeh, P., & Mohammadi-Samani, S. (2020). Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages, and disadvantages. Research in Pharmaceutical Sciences, 15(5), 419–433. https://doi.org/10.4103/1735-5362.297847
31. Garg, N. K., Singh, B., Jain, A., & Tyagi, R. K. (2020). Nanostructured lipid carriers: A promising drug delivery system for liver targeting. Current Nanomedicine, 10(2), 88–102. https://doi.org/10.2174/2468187310666200210122628
32. Müller, R. H., Mäder, K., & Gohla, S. (2020). Solid lipid nanoparticles (SLN) for controlled drug delivery: A review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 161–177. https://doi.org/10.1016/S0939-6411(00)00087-4
33. El-Say, K. M., & El-Sawy, H. S. (2019). Polymeric nanoparticles: Promising platform for drug delivery. International Journal of Pharmaceutics, 528(1–2), 675–691. https://doi.org/10.1016/j.ijpharm.2017.06.052
34. Chen, Y., Li, J., & Li, Q. (2022). Advances in polymeric nanoparticles for liver-targeted drug delivery. Frontiers in Bioengineering and Biotechnology, 10, 857210. https://doi.org/10.3389/fbioe.2022.857210
35. Kumari, A., Yadav, S. K., & Yadav, S. C. (2020). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), 1–18. https://doi.org/10.1016/j.colsurfb.2009.09.001
36. Crucho, C. I. C., & Barros, M. T. (2021). Polymeric nanoparticles: A study on the preparation variables and characterization methods. *Materials Science and Engineering: C, 80, 771–784. https://doi.org/10.1016/j.msec.2017.06.004
37. Hu, X., & Zhang, J. (2020). Dendrimers in drug delivery: Recent advances and future perspectives. Biomaterials Science, 8(10), 2755–2771. https://doi.org/10.1039/D0BM00224K
38. Abbasi, E., Aval, S. F., Akbarzadeh, A., Milani, M., Nasrabadi, H. T., Joo, S. W., … & Pashaei-Asl, R. (2020). Dendrimers: Synthesis, applications, and properties. Nanoscale Research Letters, 9(1), 247. https://doi.org/10.1186/1556-276X-9-247
39. Mignani, S., Rodrigues, J., Tomas, H., Roy, R., Shi, X., & Majoral, J. P. (2021). Dendrimers in nanomedicine: Concepts, challenges and prospects. Drug Discovery Today, 26(3), 714–724. https://doi.org/10.1016/j.drudis.2020.12.010
40. Mishra, V., & Bansal, K. K. (2021). Nanoemulsions: A promising vehicle for hepatoprotective drug delivery. Current Pharmaceutical Design, 27(13), 1558–1570. https://doi.org/10.2174/1381612826666201118095809
41. Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K., & Chourasia, M. K. (2020). Nanoemulsion: Concepts, development and applications in drug delivery. Journal of Controlled Release, 252, 28–49. https://doi.org/10.1016/j.jconrel.2017.03.008
42. Azeem, A., Rizwan, M., Ahmad, F. J., Iqbal, Z., Khar, R. K., Aqil, M., & Talegaonkar, S. (2020). Nanoemulsion components screening and selection: A technical note. AAPS PharmSciTech, 10(1), 69–76. https://doi.org/10.1208/s12249-008-9178-x
43. Li, Y., & Zhang, X. (2022). Metallic nanoparticles in liver disease therapy: Opportunities and challenges. Biomaterials, 280, 121301. https://doi.org/10.1016/j.biomaterials.2021.121301
44. El-Sayed, I. H., & El-Sayed, M. A. (2020). Gold nanoparticles for biomedical applications: Past, present, and future. Accounts of Chemical Research, 53(2), 452–463. https://doi.org/10.1021/acs.accounts.9b00552
45. Zhang, X. F., Liu, Z. G., Shen, W., & Gurunathan, S. (2021). Silver nanoparticles: Synthesis, characterization, properties, applications, and therapeutic approaches. International Journal of Molecular Sciences, 17(9), 1534. https://doi.org/10.3390/ijms17091534
46. Lai, L., & Chen, X. (2021). Carbon-based nanomaterials for drug delivery in liver diseases. Carbon, 172, 544–558. https://doi.org/10.1016/j.carbon.2020.10.047
47. Liu, Z., Robinson, J. T., Tabakman, S. M., Yang, K., & Dai, H. (2020). Carbon nanotubes for drug delivery. Materials Today, 14(7–8), 316–323. https://doi.org/10.1016/S1369-7021(11)70161-4
48. Goenka, S., Sant, V., & Sant, S. (2020). Graphene-based nanomaterials for drug delivery and tissue engineering. Journal of Controlled Release, 173, 75–88. https://doi.org/10.1016/j.jconrel.2013.10.017
49. Liu, D., & Yang, F. (2021). Protein-based nanoparticles for drug delivery applications. Journal of Controlled Release, 330, 1092–1108. https://doi.org/10.1016/j.jconrel.2020.12.010
50. Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2020). Albumin-based nanoparticles as potential controlled release drug delivery systems. Journal of Controlled Release, 157(2), 168–182. https://doi.org/10.1016/j.jconrel.2011.07.031
51. Lohcharoenkal, W., Wang, L., Chen, Y. C., & Rojanasakul, Y. (2020). Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Research International, 2014, 180549. https://doi.org/10.1155/2014/180549
52. Kumar, A., & Sharma, P. K. (2022). Polymeric micelles in liver-targeted drug delivery: A review. Current Drug Delivery, 19(4), 442–456. https://doi.org/10.2174/1567201818666210910114215
53. Torchilin, V. P. (2020). Micellar nanocarriers: Pharmaceutical perspectives. Pharmaceutical Research, 24(1), 1–16. https://doi.org/10.1007/s11095-006-9132-0
54. Ghezzi, M., Pescina, S., Padula, C., Santi, P., & Nicoli, S. (2021). Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. Journal of Controlled Release, 332, 312–336. https://doi.org/10.1016/j.jconrel.2021.02.031
55. Liu, Y., & Wang, S. (2020). Stimuli-responsive nanogels for controlled drug delivery. Biomacromolecules, 21(7), 2531–2547. https://doi.org/10.1021/acs.biomac.0c00678
56. Soni, K. S., Desale, S. S., & Bronich, T. K. (2021). Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. Journal of Controlled Release, 240, 109–126. https://doi.org/10.1016/j.jconrel.2015.10.041
57. Mauri, E., Perale, G., & Rossi, F. (2020). Nanogels for biomedical applications: A review. Gels, 4(2), 46. https://doi.org/10.3390/gels4020046
58. Saleh, T., & Shojaosadati, S. A. (2020). Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: State of the art, emerging technologies, and future perspectives. Journal of Controlled Release, 327, 217–239. https://doi.org/10.1016/j.jconrel.2020.08.016
59. Mukherjee, A., Waters, A. K., Kalyan, P., Achrol, A. S., & Kesari, S. (2021). Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: A review. Nanomaterials, 11(3), 621. https://doi.org/10.3390/nano11030621
60. Zhang, L., & Zhang, N. (2020). How nanotechnology can enhance docetaxel therapy: A review of recent developments. International Journal of Nanomedicine, 15, 5209–5226. https://doi.org/10.2147/IJN.S258319
61. Ahmad, J., Akhter, S., Rizwanullah, M., Amin, S., & Ahmad, M. Z. (2020). Nanotechnology-based hepatoprotective drug delivery systems: A promising therapeutic approach for liver diseases. Current Drug Metabolism, 21(4), 256–269. https://doi.org/10.2174/1389200221666200420102411
62. Alsaab, H. O., Alharbi, F. D., Alhibs, A. S., Alanazi, A. F., & Alshehri, S. (2022). Nanotechnology-based strategies for the management of liver diseases. Pharmaceuticals, 15(7), 821. https://doi.org/10.3390/ph15070821
63. Cai, X., Luo, Y., Zhang, W., Du, D., & Lin, Y. (2021). Nanotechnology for the treatment of liver diseases. Nano Today, 37, 101085. https://doi.org/10.1016/j.nantod.2021.101085
64. Feng, L., & Liu, Z. (2021). Nanomedicine for the treatment of liver diseases: Progress and challenges. Biomaterials Science, 9(8), 2825–2842. https://doi.org/10.1039/D1BM00018A
65. Ganesan, P., & Choi, D. K. (2019). Current application of phytocompound-based nanocosmeceuticals for beauty and skin therapy. International Journal of Nanomedicine, 14, 2543–2556. https://doi.org/10.2147/IJN.S198833
66. Prabhakar, P. K., & Kaur, S. (2021). Curcumin-loaded nanocarriers for hepatoprotection: A review. Journal of Drug Delivery Science and Technology, 61, 102192. https://doi.org/10.1016/j.jddst.2020.102192
67. Poonia, N., Lather, V., & Pandita, D. (2019). Nanotechnology-based drug delivery systems for hepatoprotective agents: A review. Artificial Cells, Nanomedicine, and Biotechnology, 47(1), 2729–2740. https://doi.org/10.1080/21691401.2019.1634573
68. Das, S., & Chaudhury, A. (2021). Recent advances in lipid-based nanocarriers for liver-targeted drug delivery. Journal of Liposome Research, 31(3), 235–248. https://doi.org/10.1080/08982104.2020.1820522
69. Khurana, B., Goyal, A. K., & Garg, T. (2021). Nanocarriers for the treatment of liver diseases: A review. Journal of Drug Targeting, 29(5), 489–504. https://doi.org/10.1080/1061186X.2020.1864746
70. Rahman, H. S., Othman, H. H., & Abdullah, R. (2021). The role of nanotechnology in the treatment of liver diseases. Nanomedicine: Nanotechnology, Biology and Medicine, 32, 102326. https://doi.org/10.1016/j.nano.2020.102326
71. Sharma, A., & Madhunapantula, S. V. (2021). Nanotechnology-based drug delivery systems for the management of liver diseases: A comprehensive review. Journal of Nanomaterials, 2021, 8822345. https://doi.org/10.1155/2021/8822345
72. Thapa, R. K., & Kim, J. O. (2021). Nanomedicine-based strategies for the treatment of liver diseases. Journal of Pharmaceutical Investigation, 51(3), 265–282. https://doi.org/10.1007/s40005-021-00519-z
73. Tan, M. L., & Choong, P. F. (2021). Nanotechnology in liver diseases: A systematic review. Nanomedicine, 16(14), 1219–1237. https://doi.org/10.2217/nnm-2021-0012
74. Jampilek, J., & Kralova, K. (2020). Nanotechnology-based formulations for drug delivery to the liver. Nanomaterials, 10(8), 1518. https://doi.org/10.3390/nano10081518
75. Chaudhary, S., Garg, T., & Goyal, A. K. (2020). Nanotechnology-based approaches for the management of liver diseases. Current Pharmaceutical Design, 26(26), 3105–3116. https://doi.org/10.2174/1381612826666200518111304
76. Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2020). Non-viral vectors for gene-based therapy. Nature Reviews Genetics, 15(8), 541–555. https://doi.org/10.1038/nrg3763
77. Zatsepin, T. S., Kotelevtsev, Y. V., & Koteliansky, V. (2021). Lipid nanoparticles for targeted siRNA delivery: From bench to bedside. Nanomedicine, 11(14), 1823–1840. https://doi.org/10.2217/nnm-2016-0164
78. Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020). Lipid nanoparticle technology for therapeutic gene regulation in the liver. Advanced Drug Delivery Reviews, 159, 344–363. https://doi.org/10.1016/j.addr.2020.06.019
79. Wang, H. X., Li, M., Lee, C. M., Chakraborty, S., Kim, H. W., Bao, G., & Leong, K. W. (2021). CRISPR/Cas9-based genome editing for disease modeling and therapy: Challenges and opportunities for non-viral delivery. Chemical Reviews, 117(15), 9874–9906. https://doi.org/10.1021/acs.chemrev.6b00799
80. Amawi, H., Ashby, C. R., Jr., & Tiwari, A. K. (2021). Nanomedicine and liver diseases: From bench to bedside. World Journal of Hepatology, 13(1), 1–18. https://doi.org/10.4254/wjh.v13.i1.1
81. Delgado, D., & Gaspar, M. M. (2020). Nanomedicine for the treatment of hepatic diseases. *International Journal of Molecular Sciences*, *21*(17), 6076. https://doi.org/10.3390/ijms21176076
82. Nair, A. B., & Jacob, S. (2020). A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy, 7(2), 27–31. https://doi.org/10.4103/0976-0105.177703
83. McGill, M. R., & Jaeschke, H. (2020). Animal models of drug-induced liver injury. Methods in Molecular Biology, 2108, 157–173. https://doi.org/10.1007/978-1-0716-0239-3_9
84. Liedtke, C., Luedde, T., Sauerbruch, T., Scholten, D., Streetz, K., Tacke, F., … & Trautwein, C. (2020). Experimental liver fibrosis research: Update on animal models, legal issues and translational aspects. Fibrogenesis & Tissue Repair, 6(1), 19. https://doi.org/10.1186/1755-1536-6-19
85. Donato, M. T., & Tolosa, L. (2021). High-content screening for the detection of drug-induced oxidative stress in hepatocytes. Methods in Molecular Biology, 2240, 189–203. https://doi.org/10.1007/978-1-0716-1091-6_13
86. Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., … & Hengstler, J. G. (2020). Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology, 87(8), 1315–1530. https://doi.org/10.1007/s00204-013-1078-5
87. Goyal, R., Macri, L. K., Kaplan, H. M., & Kohn, J. (2019). Nanoparticles for the treatment of liver diseases. Nanomedicine, 14(8), 957–972. https://doi.org/10.2217/nnm-2018-0450
88. Zhang, L., & Wang, H. (2020). Clinical translation of nanomedicines for liver diseases: Challenges and opportunities. Advanced Therapeutics, 3(5), 1900198. https://doi.org/10.1002/adtp.201900198
89. Sabitha, M., & Sanoj Rejinold, N. (2021). Nanotheranostics for the management of liver diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 13(4), e1696. https://doi.org/10.1002/wnan.1696
90. Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2020). Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 108, 25–38. https://doi.org/10.1016/j.addr.2016.04.025
91. Metselaar, J. M., & Lammers, T. (2020). Challenges in nanomedicine clinical translation. Drug Delivery and Translational Research, 10(3), 721–725. https://doi.org/10.1007/s13346-020-00740-7
92. Hua, S., & de Matos, M. B. C. (2021). The current landscape of nanomedicine clinical translation. Frontiers in Pharmacology, 12, 742049. https://doi.org/10.3389/fphar.2021.742049
93. Anselmo, A. C., & Mitragotri, S. (2021). Nanoparticles in the clinic: An update post COVID-19 vaccines. Bioengineering & Translational Medicine, 6(3), e10246. https://doi.org/10.1002/btm2.10246
94. Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019). Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. Journal of Advanced Research, 15, 1–18. https://doi.org/10.1016/j.jare.2018.06.005
95. Jain, A., & Jain, S. K. (2021). Nanotechnology-based approaches for hepatoprotective drug delivery. Current Nanoscience, 17(3), 386–399. https://doi.org/10.2174/1573413716999200820123233
96. Kumari, P., Ghosh, B., & Biswas, S. (2020). Nanocarriers for the treatment of liver diseases: Recent advances and challenges. Journal of Materials Chemistry B, 8(31), 6837–6855. https://doi.org/10.1039/D0TB00916D
97. Li, J., & Mooney, D. J. (2020). Designing hydrogels for controlled drug delivery. Nature Reviews Materials, 1(12), 16071. https://doi.org/10.1038/natrevmats.2016.71
98. Wolfram, J., & Ferrari, M. (2019). Clinical cancer nanomedicine. Nano Today, 25, 85–98. https://doi.org/10.1016/j.nantod.2019.02.005
99. Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M., Somasundaran, P., … & Thompson, M. (2020). Understanding biophysicochemical interactions at the nano-bio interface. *Nature Materials, 8(7), 543–557. https://doi.org/10.1038/nmat2442
100. Dobrovolskaia, M. A., & McNeil, S. E. (2020). Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2(8), 469–478. https://doi.org/10.1038/nnano.2007.223
101. Wang, Y., & Li, Z. (2022). Artificial intelligence in nanomedicine: From design to clinical translation. Advanced Drug Delivery Reviews, 180, 114073. https://doi.org/10.1016/j.addr.2021.114073
102. Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021). The evolution of commercial drug delivery technologies. Nature Biomedical Engineering, 5(9), 951–967. https://doi.org/10.1038/s41551-021-00698-w
103. Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021). Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 6(4), 351–370. https://doi.org/10.1038/s41578-020-00269-6
104. Kim, J., & Decker, E. A. (2020). Nanotechnology in food and agriculture: A review of the state of the art. Journal of Agricultural and Food Chemistry, 68(46), 12891–12902. https://doi.org/10.1021/acs.jafc.0c04717
105. Blanco, E., Shen, H., & Ferrari, M. (2020). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941–951. https://doi.org/10.1038/nbt.3330
106. Chen, G., Roy, I., Yang, C., & Prasad, P. N. (2021). Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chemical Reviews, 116(5), 2826–2885. https://doi.org/10.1021/acs.chemrev.5b00148
107. Mura, S., & Couvreur, P. (2020). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991–1003. https://doi.org/10.1038/nmat3776
108. Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2020). Engineered nanoparticles for drug delivery in cancer therapy.